Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 24 | 2024 | 16718 | 0.650 |
Why?
|
Anti-HIV Agents | 12 | 2021 | 4256 | 0.520 |
Why?
|
Disease Outbreaks | 3 | 2021 | 1772 | 0.460 |
Why?
|
RNA, Viral | 10 | 2023 | 2902 | 0.370 |
Why?
|
Sarcoma, Kaposi | 2 | 2024 | 370 | 0.330 |
Why?
|
Nucleosomes | 1 | 2012 | 494 | 0.310 |
Why?
|
Influenza, Human | 2 | 2016 | 1480 | 0.300 |
Why?
|
Lamivudine | 2 | 2018 | 342 | 0.290 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2018 | 215 | 0.280 |
Why?
|
Anti-Retroviral Agents | 3 | 2021 | 1715 | 0.270 |
Why?
|
Population Surveillance | 1 | 2016 | 2616 | 0.270 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 821 | 0.260 |
Why?
|
Control Groups | 1 | 2023 | 105 | 0.230 |
Why?
|
Virus Shedding | 2 | 2023 | 108 | 0.210 |
Why?
|
Herpesvirus 8, Human | 1 | 2024 | 258 | 0.200 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2016 | 459 | 0.200 |
Why?
|
Alkynes | 1 | 2021 | 306 | 0.190 |
Why?
|
South Africa | 2 | 2016 | 1731 | 0.190 |
Why?
|
Atrial Fibrillation | 6 | 2014 | 5034 | 0.180 |
Why?
|
Biological Assay | 1 | 2023 | 652 | 0.180 |
Why?
|
Chromatin | 1 | 2012 | 2934 | 0.180 |
Why?
|
Cyclopropanes | 1 | 2021 | 416 | 0.180 |
Why?
|
Benzoxazines | 1 | 2021 | 301 | 0.180 |
Why?
|
Nitriles | 2 | 2022 | 952 | 0.170 |
Why?
|
Cytomegalovirus | 2 | 2023 | 732 | 0.170 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 90 | 0.170 |
Why?
|
Pyrimidines | 2 | 2022 | 2940 | 0.170 |
Why?
|
Galectins | 1 | 2021 | 268 | 0.170 |
Why?
|
Bleomycin | 1 | 2020 | 501 | 0.170 |
Why?
|
Outpatients | 2 | 2023 | 1486 | 0.170 |
Why?
|
HIV | 6 | 2023 | 1604 | 0.160 |
Why?
|
Genitalia | 1 | 2018 | 112 | 0.160 |
Why?
|
Body Composition | 2 | 2019 | 2400 | 0.160 |
Why?
|
Vincristine | 1 | 2020 | 1036 | 0.150 |
Why?
|
Osteoprotegerin | 1 | 2018 | 176 | 0.150 |
Why?
|
Arginine | 1 | 2021 | 944 | 0.150 |
Why?
|
DNA | 1 | 2012 | 7303 | 0.150 |
Why?
|
DNA, Viral | 2 | 2023 | 2226 | 0.150 |
Why?
|
Models, Statistical | 1 | 2012 | 5102 | 0.140 |
Why?
|
Antiviral Agents | 3 | 2023 | 2987 | 0.140 |
Why?
|
RANK Ligand | 1 | 2018 | 326 | 0.140 |
Why?
|
Inflammation | 4 | 2023 | 10634 | 0.140 |
Why?
|
Humans | 54 | 2024 | 744220 | 0.140 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2020 | 657 | 0.140 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2022 | 2234 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 692 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 623 | 0.140 |
Why?
|
Hong Kong | 1 | 2015 | 148 | 0.130 |
Why?
|
Bone Density | 2 | 2020 | 3468 | 0.130 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1043 | 0.130 |
Why?
|
Death | 1 | 2019 | 678 | 0.120 |
Why?
|
Adult | 27 | 2023 | 214035 | 0.120 |
Why?
|
Singapore | 1 | 2015 | 295 | 0.120 |
Why?
|
Pyrazoles | 2 | 2022 | 1973 | 0.120 |
Why?
|
Abdominal Fat | 1 | 2016 | 223 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 572 | 0.120 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2015 | 137 | 0.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2021 | 1873 | 0.110 |
Why?
|
Lipoproteins, LDL | 1 | 2016 | 639 | 0.110 |
Why?
|
Waist Circumference | 1 | 2017 | 917 | 0.110 |
Why?
|
Contact Tracing | 1 | 2015 | 273 | 0.110 |
Why?
|
Japan | 1 | 2016 | 1361 | 0.110 |
Why?
|
HIV-1 | 3 | 2018 | 6938 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 638 | 0.100 |
Why?
|
Intra-Abdominal Fat | 1 | 2017 | 591 | 0.100 |
Why?
|
Antibodies, Monoclonal | 6 | 2023 | 9275 | 0.100 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 547 | 0.100 |
Why?
|
C-Reactive Protein | 3 | 2021 | 3778 | 0.100 |
Why?
|
Genome, Fungal | 1 | 2012 | 204 | 0.090 |
Why?
|
Middle Aged | 21 | 2023 | 213367 | 0.090 |
Why?
|
Gonadal Steroid Hormones | 1 | 2014 | 711 | 0.090 |
Why?
|
Viral Load | 4 | 2023 | 3300 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2015 | 2970 | 0.080 |
Why?
|
Male | 28 | 2023 | 350027 | 0.080 |
Why?
|
Risk Assessment | 4 | 2014 | 23337 | 0.080 |
Why?
|
Markov Chains | 1 | 2012 | 969 | 0.080 |
Why?
|
Female | 28 | 2023 | 380197 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2022 | 3863 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1838 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2019 | 3278 | 0.080 |
Why?
|
Antibodies, Viral | 3 | 2023 | 3176 | 0.070 |
Why?
|
Adiposity | 1 | 2017 | 1807 | 0.070 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 391 | 0.070 |
Why?
|
Bayes Theorem | 1 | 2015 | 2309 | 0.070 |
Why?
|
Oxazines | 2 | 2018 | 298 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4935 | 0.070 |
Why?
|
Age Factors | 4 | 2016 | 18367 | 0.070 |
Why?
|
HIV Protease Inhibitors | 2 | 2021 | 430 | 0.070 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2014 | 1573 | 0.070 |
Why?
|
Kinetics | 2 | 2023 | 6474 | 0.070 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11728 | 0.070 |
Why?
|
Protease Inhibitors | 2 | 2020 | 791 | 0.060 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 49 | 0.060 |
Why?
|
Ritonavir | 2 | 2016 | 322 | 0.060 |
Why?
|
Menopause | 1 | 2012 | 1626 | 0.060 |
Why?
|
ROC Curve | 1 | 2012 | 3527 | 0.060 |
Why?
|
Pyridones | 2 | 2018 | 712 | 0.060 |
Why?
|
Pandemics | 1 | 2023 | 8387 | 0.060 |
Why?
|
WT1 Proteins | 1 | 2024 | 178 | 0.060 |
Why?
|
Antibodies, Neutralizing | 2 | 2022 | 1978 | 0.050 |
Why?
|
Half-Life | 1 | 2023 | 659 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5096 | 0.050 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 31 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6196 | 0.050 |
Why?
|
Prospective Studies | 7 | 2021 | 53280 | 0.050 |
Why?
|
Metabolic Clearance Rate | 1 | 2021 | 379 | 0.050 |
Why?
|
Heart Failure | 3 | 2013 | 10905 | 0.050 |
Why?
|
Young Adult | 5 | 2019 | 56436 | 0.050 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 2752 | 0.050 |
Why?
|
Janus Kinases | 1 | 2021 | 244 | 0.050 |
Why?
|
Adipokines | 1 | 2022 | 319 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2023 | 12035 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20123 | 0.040 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2019 | 92 | 0.040 |
Why?
|
Aged | 9 | 2019 | 163253 | 0.040 |
Why?
|
Weight Gain | 2 | 2022 | 2292 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2024 | 1731 | 0.040 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2019 | 138 | 0.040 |
Why?
|
Etoposide | 1 | 2020 | 639 | 0.040 |
Why?
|
Aged, 80 and over | 4 | 2016 | 57768 | 0.040 |
Why?
|
Incidence | 5 | 2014 | 20945 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2023 | 847 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2019 | 244 | 0.040 |
Why?
|
Africa | 1 | 2020 | 673 | 0.040 |
Why?
|
Piperazines | 2 | 2018 | 2491 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6485 | 0.040 |
Why?
|
Drug Interactions | 1 | 2021 | 1458 | 0.040 |
Why?
|
Immune System | 1 | 2021 | 805 | 0.030 |
Why?
|
Stroke | 2 | 2021 | 9981 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1769 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.030 |
Why?
|
Aging | 1 | 2014 | 8661 | 0.030 |
Why?
|
Algorithms | 2 | 2013 | 13885 | 0.030 |
Why?
|
Infant | 1 | 2016 | 35129 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 1725 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 40992 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2013 | 12355 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19907 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2023 | 63119 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 2014 | 918 | 0.030 |
Why?
|
HIV Integrase Inhibitors | 1 | 2015 | 142 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2021 | 1401 | 0.030 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 820 | 0.030 |
Why?
|
Heart Murmurs | 1 | 2013 | 94 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1836 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2021 | 21752 | 0.030 |
Why?
|
Iceland | 1 | 2013 | 183 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2749 | 0.030 |
Why?
|
Paclitaxel | 1 | 2020 | 1707 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2023 | 2708 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2021 | 3201 | 0.030 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2015 | 615 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3584 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1880 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4559 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13990 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15070 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3478 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2187 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8343 | 0.020 |
Why?
|
Body Weight | 1 | 2021 | 4666 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4929 | 0.020 |
Why?
|
Child | 1 | 2016 | 77679 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 85759 | 0.020 |
Why?
|
Netherlands | 1 | 2013 | 2170 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6367 | 0.020 |
Why?
|
Age Distribution | 1 | 2014 | 2903 | 0.020 |
Why?
|
Time Factors | 2 | 2023 | 40063 | 0.020 |
Why?
|
Europe | 1 | 2014 | 3339 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2013 | 859 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6757 | 0.020 |
Why?
|
Developing Countries | 1 | 2020 | 2814 | 0.020 |
Why?
|
Body Mass Index | 2 | 2017 | 12718 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 77426 | 0.020 |
Why?
|
Software | 1 | 2021 | 4442 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25043 | 0.020 |
Why?
|
Risk Factors | 4 | 2014 | 72280 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10250 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5953 | 0.020 |
Why?
|
Self Report | 1 | 2017 | 3558 | 0.020 |
Why?
|
Cohort Studies | 3 | 2013 | 40559 | 0.020 |
Why?
|
Antigens, CD | 1 | 2016 | 4026 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8321 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.020 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 5755 | 0.020 |
Why?
|
Hospitalization | 1 | 2023 | 10262 | 0.010 |
Why?
|
Prognosis | 2 | 2014 | 29050 | 0.010 |
Why?
|
Overweight | 1 | 2013 | 2370 | 0.010 |
Why?
|
United States | 3 | 2014 | 69867 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12781 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12244 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11493 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29784 | 0.010 |
Why?
|
Smoking | 1 | 2013 | 8986 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8480 | 0.010 |
Why?
|
Neoplasms | 1 | 2021 | 21672 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39045 | 0.010 |
Why?
|
Concepts
(197)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(18)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_